<DOC>
	<DOC>NCT00912288</DOC>
	<brief_summary>No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.</brief_summary>
	<brief_title>A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease</brief_title>
	<detailed_description>This study was terminated on May 7, 2010 due to modification of the dimebon development plan following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Are men and women â‰¥ 50 years of age with a diagnosis of Alzheimers disease. Have a MiniMental State Exam between 5 and 14 inclusive. Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study. Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care. Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study. Dementia other than Alzheimers disease. Any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Alzheimer disease moderate-to-severe memantine safety and efficacy</keyword>
</DOC>